Wave Life Sciences Q3 2025 Earnings Preview

* Wave Life Sciences (WVE [https://seekingalpha.com/symbol/WVE]) is scheduled to announce Q3 earnings results on Monday, November 10th, before market open.
The consensus EPS Estimate is -$0.30 [https://seekingalpha.com/symbol/WVE/earnings/estimates] (+36.2% Y/Y) and the consensus Revenue Estimate is $10.53M (+237.1% Y/Y).Over the last 2 years, WVE has beaten EPS estimates [https://seekingalpha.com/symbol/WVE/earnings/eps-surprise-summary] 50% of the time and has beaten revenue estimates 50% of the time.

MORE ON WAVE LIFE SCIENCES

* Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics Transcript [https://seekingalpha.com/article/4835098-wave-life-sciences-ltd-wve-spotlight-on-rna-editing-and-rnai-pipeline-and-clinical-advances]
* Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics - Slideshow [https://seekingalpha.com/article/4835099-wave-life-sciences-ltd-wve-spotlight-on-rna-editing-and-rnai-pipeline-and-clinical-advances]
* Wave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference Transcript [https://seekingalpha.com/article/4819106-wave-life-sciences-ltd-special-call]
* Wave Life Sciences drops after trial data for GSK-partnered RNA-editing therapy [https://seekingalpha.com/news/4491649-wave-life-sciences-reports-durable-aat-protein-production-with-repeat-doses-of-wve-006-stock-down-21]
* Wave Life Sciences gains as JPMorgan suspends rating (update) [https://seekingalpha.com/news/4486208-wave-life-sciences-gains-as-jpmorgan-suspends-rating]